Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Description of selected characteristics in subjects

From: Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment

  PMD reduction ≤10% PMD reduction >10% P
  n = 247 n = 31  
Baseline characteristics    
  Age (years) 63.8 ± 6.2 61.5 ± 5.9 0.05
  BMI (kg/m2) 25.4 ± 3.7 24.1 ± 4 0.02
  HRT ever    0.10
   No 106 (42.9) 8 (25.8)  
   Yes 141 (57.1) 23 (74.2)  
  Baseline PMD 14.7 ± 9.5 32 ± 9.1 <0.001
  Time between mammograms (years) 1.9 ± 0.6 2.0 ± 0.5 0.30
Tumor characteristics    
  ER status    0.15
  Positive 167 (67.6) 26 (83.9)  
  Negative 29 (11.7) 1 (3.2)  
  Missing 51 (20.6) 4 (12.9)  
Treatment    
  Chemotherapy    0.48
   No 236 (95.5) 31 (100)  
   Yes 11 (4.5) 0 (0)  
  Radiotherapy    0.60
   No 159 (64.4) 22 (71)  
   Yes 88 (35.6) 9 (29)  
  Tamoxifen (mg)    
   20 137 (55.5) 13 (41.9) 0.47
   40 50 (20.2) 9 (29.0)  
   20 and 40 57 (23.1) 9 (29.0)  
  *Others 3 (1.2) 0 (0)  
  1. Description of selected characteristics in subjects with less than or greater than a 10% percent mammographic density (PMD) reduction, with P values for association. Categorical variables (frequencies (%)) were assessed for association using chi-squared tests, while continuous variables (means ± standard deviation (SD)) were assessed using Kruskal-Wallis tests. *One woman was prescribed an unknown dose of tamoxifen. Two women were prescribed tamoxifen citrate and two were prescribed toremifene, a chlorinated derivative of tamoxifen. HRT, hormone replacement therapy; BMI, body mass index; ER, estrogen receptor.